Raymond James downgraded Cano Health from Outperform to Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2023 | Buy → Hold | Jefferies | |
| 8/11/2023 | $4.00 → $0.80 | Buy → Neutral | Citigroup |
| 1/6/2023 | $12.00 → $1.25 | Buy → Neutral | UBS |
| 1/5/2023 | Outperform → Peer Perform | Wolfe Research | |
| 12/13/2022 | $1.50 | Underperform | BofA Securities |
| 11/10/2022 | $10.00 → $3.00 | Outperform → Market Perform | Cowen |
| 11/10/2022 | Outperform → Mkt Perform | Raymond James | |
| 10/27/2022 | $10.00 → $5.00 | Outperform → Neutral | Credit Suisse |
4 - Cano Health, Inc. (0001800682) (Issuer)
4 - Cano Health, Inc. (0001800682) (Issuer)
4 - Cano Health, Inc. (0001800682) (Issuer)
8-K - Cano Health, Inc. (0001800682) (Filer)
8-K - Cano Health, Inc. (0001800682) (Filer)
25-NSE - Cano Health, Inc. (0001800682) (Subject)
Emergence from Chapter 11 Expected in Third Quarter of 2024 MIAMI, May 21, 2024 /PRNewswire/ -- Cano Health, Inc. (NYSE: CANO) ("Cano Health" or the "Company"), a leading value-based primary care provider and population health company, today announced a global agreement with the Unsecured Creditors Committee representing the interests of the Company's general unsecured creditors, with the support of the Ad Hoc Lender Group. It also received approval of its Disclosure Statement by the U.S. Bankruptcy Court for the District of Delaware (the "Court"), paving the way to solicit creditor approval of its Plan of Reorganization and its expected emergence from Chapter 11 in the third quarter. Mark
MIAMI, Feb. 5, 2024 /PRNewswire/ -- Cano Health, Inc. (NYSE:CANO) ("Cano Health" or the "Company") announced today that on February 5, 2024, the New York Stock Exchange (the "NYSE") notified the Company that the NYSE had determined to (a) commence proceedings to delist the Company's Class A common stock, par value $0.01 per share ("Common Stock") and (b) immediately suspend trading in the Company's Common Stock pursuant to Section 802.01D of the NYSE Listed Company Manual after the Company filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware on February 4, 2024.
Positions the Company to Advance Its Ongoing Transformation Plan Designed to Significantly Reduce Costs, Enhance Productivity, and Improve Cash Flow Receives Commitment for $150 Million in New Capital Ensures Patients Continue to Receive High-Quality Care Across Medical Centers MIAMI, Feb. 4, 2024 /PRNewswire/ -- Cano Health, Inc. (NYSE:CANO) ("Cano Health" or the "Company"), a leading value-based primary care provider and population health company, today announced that it has entered into a Restructuring Support Agreement (the "RSA") with lenders (the "Ad Hoc Lender Group") holding approximately 86% of its secured revolving and term loan debt and 92% of its senior unsecured notes. This a
Jefferies downgraded Cano Health from Buy to Hold
Citigroup downgraded Cano Health from Buy to Neutral and set a new price target of $0.80 from $4.00 previously
UBS downgraded Cano Health from Buy to Neutral and set a new price target of $1.25 from $12.00 previously